Cardiovascular Systems, Inc.
CSII · NASDAQ
6/30/2022 | 6/30/2021 | 6/30/2020 | 6/30/2019 | |
|---|---|---|---|---|
| Revenue | $236,222 | $258,973 | $236,545 | $248,017 |
| % Growth | -8.8% | 9.5% | -4.6% | – |
| Cost of Goods Sold | $63,440 | $61,131 | $48,759 | $47,680 |
| Gross Profit | $172,782 | $197,842 | $187,786 | $200,337 |
| % Margin | 73.1% | 76.4% | 79.4% | 80.8% |
| R&D Expenses | $36,720 | $41,061 | $43,355 | $33,462 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $170,526 | $167,498 | $169,969 | $167,700 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $167,700 |
| Other Operating Expenses | $1,342 | $1,216 | $1,234 | $760 |
| Operating Expenses | $208,588 | $209,775 | $214,558 | $201,162 |
| Operating Income | -$35,806 | -$11,933 | -$26,772 | -$825 |
| % Margin | -15.2% | -4.6% | -11.3% | -0.3% |
| Other Income/Exp. Net | -$817 | -$1,236 | -$233 | $760 |
| Pre-Tax Income | -$36,623 | -$13,169 | -$27,005 | -$65 |
| Tax Expense | $310 | $252 | $231 | $190 |
| Net Income | -$36,933 | -$13,421 | -$27,236 | -$255 |
| % Margin | -15.6% | -5.2% | -11.5% | -0.1% |
| EPS | -0.94 | -0.35 | -0.79 | -0.008 |
| % Growth | -168.6% | 55.7% | -10,294.7% | – |
| EPS Diluted | -0.94 | -0.35 | -0.79 | -0.008 |
| Weighted Avg Shares Out | 39,230 | 38,832 | 34,276 | 33,536 |
| Weighted Avg Shares Out Dil | 39,230 | 38,832 | 34,276 | 33,536 |
| Supplemental Information | – | – | – | – |
| Interest Income | $817 | $499 | $1,740 | $2,444 |
| Interest Expense | $1,634 | $1,735 | $1,973 | $1,684 |
| Depreciation & Amortization | $1,342 | $1,216 | $1,234 | $3,446 |
| EBITDA | -$33,647 | -$10,218 | -$23,798 | $5,065 |
| % Margin | -14.2% | -3.9% | -10.1% | 2% |